Display options
Cite
Ottka C, Weber C, Müller E, et al. Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs. Metabolomics. 2021;17(6):54doi: 10.1007/s11306-021-01803-5.
Ottka, C., Weber, C., Müller, E., & Lohi, H. (2021). Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs. Metabolomics : Official journal of the Metabolomic Society, 17(6), 54. https://doi.org/10.1007/s11306-021-01803-5
Ottka, Claudia, et al. "Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs." Metabolomics : Official journal of the Metabolomic Society vol. 17,6 (2021): 54. doi: https://doi.org/10.1007/s11306-021-01803-5
Ottka C, Weber C, Müller E, Lohi H. Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs. Metabolomics. 2021 Jun 02;17(6):54. doi: 10.1007/s11306-021-01803-5. PMID: 34076758; PMCID: PMC8172515.
Copy Download .nbib Format: NLM
Share it on

Metabolomics. 2021 Jun 02;17(6):54. doi: 10.1007/s11306-021-01803-5.

Serum NMR metabolomics uncovers multiple metabolic changes in phenobarbital-treated dogs.

Metabolomics : Official journal of the Metabolomic Society

Claudia Ottka, Corinna Weber, Elisabeth Müller, Hannes Lohi

Affiliations

  1. PetBiomics Ltd., Helsinki, Finland. [email protected].
  2. Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland. [email protected].
  3. Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland. [email protected].
  4. Folkhälsan Research Center, Helsinki, Finland. [email protected].
  5. LABOKLIN GmbH & Co KG, Bad Kissingen, Germany.
  6. PetBiomics Ltd., Helsinki, Finland.
  7. Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.
  8. Department of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
  9. Folkhälsan Research Center, Helsinki, Finland.

PMID: 34076758 PMCID: PMC8172515 DOI: 10.1007/s11306-021-01803-5

Abstract

INTRODUCTION: Phenobarbital is a commonly used anticonvulsant for the treatment of canine epileptic seizures. In addition to its central nervous system (CNS) depressing effects, long-term phenobarbital administration affects liver function. However, broader metabolic consequences of phenobarbital treatment are poorly characterized.

OBJECTIVES: To identify metabolic changes in the sera of phenobarbital-treated dogs and to investigate the relationship between serum phenobarbital concentration and metabolite levels.

METHODS: Leftovers of clinical samples were used: 58 cases with phenobarbital concentrations ranging from 7.8 µg/mL to 50.8 µg/mL, and 25 controls. The study design was cross-sectional. The samples were analyzed by a canine-specific

RESULTS: Increasing concentrations of glycoprotein acetyls, LDL particle size, palmitic acid, and saturated fatty acids, and decreasing concentrations of albumin, glutamine, histidine, LDL particle concentration, multiple HDL measures, and polyunsaturated fatty acids increased the odds of the sample belonging to the phenobarbital-treated group, having a p-value < .0033, and area under the curve (AUC) > .7. Albumin and glycoprotein acetyls had the best discriminative ability between the groups (AUC: .94). No linear associations between phenobarbital and metabolite concentrations were observed.

CONCLUSION: The identified metabolites are known to associate with, for example, liver and CNS function, inflammatory processes and drug binding. The lack of a linear association to phenobarbital concentration suggests that other factors than the blood phenobarbital concentration contribute to the magnitude of metabolic changes.

Keywords: Anticonvulsant; Canine; Epilepsy; Metabolism; Phenobarbital

References

  1. Br J Pharmacol. 2012 Dec;167(7):1398-414 - PubMed
  2. J Vet Intern Med. 2000 Mar-Apr;14(2):165-71 - PubMed
  3. Pharmacol Rev. 1988 Mar;40(1):1-47 - PubMed
  4. Am J Epidemiol. 2017 Nov 1;186(9):1084-1096 - PubMed
  5. Int J Epidemiol. 2015 Apr;44(2):623-37 - PubMed
  6. Drug Metab Rev. 2001 May;33(2):161-235 - PubMed
  7. J Vet Pharmacol Ther. 2002 Apr;25(2):121-7 - PubMed
  8. N Am J Med Sci. 2015 Jul;7(7):317-21 - PubMed
  9. Ann Neurol. 1989 Mar;25(3):213-20 - PubMed
  10. Cell Syst. 2015 Oct 28;1(4):293-301 - PubMed
  11. J Transl Med. 2017 Oct 27;15(1):219 - PubMed
  12. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):65-70 - PubMed
  13. Mol Pharmacol. 1997 Mar;51(3):363-9 - PubMed
  14. J Vet Intern Med. 2016 Mar-Apr;30(2):477-90 - PubMed
  15. PLoS Med. 2014 Feb 25;11(2):e1001606 - PubMed
  16. PLoS One. 2013 Oct 24;8(10):e76137 - PubMed
  17. J Am Vet Med Assoc. 1995 Nov 15;207(10):1305-7 - PubMed
  18. Clin Chem. 2015 May;61(5):714-23 - PubMed
  19. Inflammation. 1991 Dec;15(6):471-80 - PubMed
  20. Hepatology. 1994 Dec;20(6):1584-8 - PubMed
  21. Am J Vet Res. 1989 Aug;50(8):1343-7 - PubMed
  22. Vet J. 2010 Jan;183(1):12-21 - PubMed
  23. PLoS Comput Biol. 2018 Apr 16;14(4):e1006040 - PubMed
  24. Brain Res. 1982 Dec 16;253(1-2):153-60 - PubMed
  25. J Am Vet Med Assoc. 1991 Oct 15;199(8):1060-6 - PubMed
  26. Biochem J. 1997 Nov 15;328 ( Pt 1):159-63 - PubMed
  27. Brain Res. 1982 Mar 18;236(1):157-71 - PubMed
  28. Biochem Cell Biol. 2006 Apr;84(2):215-31 - PubMed
  29. Neurochem Res. 2004 Jan;29(1):319-24 - PubMed
  30. Acta Pharmacol Sin. 2002 Apr;23(4):361-6 - PubMed
  31. Epilepsia. 2002 Jul;43(7):703-10 - PubMed
  32. Adv Neurobiol. 2016;13:351-400 - PubMed
  33. Pharmacol Biochem Behav. 1999 Nov;64(3):513-8 - PubMed
  34. J Vet Intern Med. 2000 Mar-Apr;14(2):157-64 - PubMed
  35. J Cell Physiol. 2005 Aug;204(2):392-401 - PubMed
  36. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3600-3609 - PubMed
  37. Epilepsia. 2002 Jan;43(1):103-4 - PubMed

Publication Types